Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

计划入组 510 人 · 首次发布于 2021 年 11 月 24 日

Genotype-Phenotype Correlations in Patients With Alport Syndrome

计划入组 8,165 人 · 首次发布于 2021 年 7 月 1 日

A Study of ELX-02 in Patients With Alport Syndrome

计划入组 3 人 · 首次发布于 2022 年 7 月 7 日

COL7A1 gene-modified autologous fibroblasts

COL7A1 gene editing therapy (Trucode Gene)

GLP-1 analog-COL3A1 fusion protein

The Coca-Cola Company

United States

SonoThera Demonstrates Novel Ultrasound Gene Delivery for X-Linked Alport Syndrome Treatment

Bayer Initiates Phase IIa Trial for Novel Alport Syndrome Treatment BAY 3401016

FDA's Q-Collar Approval Under Fire as Internal Reviewers Warned of Flawed Evidence